FS ReportsPub Date : 2025-12-01Epub Date: 2025-09-15DOI: 10.1016/j.xfre.2025.09.005
Quinn Rhodes M.D. , Terri L. Woodard M.D. , Laura Detti M.D. , Michael Roth M.D. , Susan Shott Ph.D. , Jennifer McQuade M.D. , Laurie J. McKenzie M.D.
{"title":"Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma","authors":"Quinn Rhodes M.D. , Terri L. Woodard M.D. , Laura Detti M.D. , Michael Roth M.D. , Susan Shott Ph.D. , Jennifer McQuade M.D. , Laurie J. McKenzie M.D.","doi":"10.1016/j.xfre.2025.09.005","DOIUrl":"10.1016/j.xfre.2025.09.005","url":null,"abstract":"<div><h3>Objective</h3><div>To study the reproductive impact of immune checkpoint inhibitor (ICI) therapy in cis-females with melanoma.</div></div><div><h3>Design</h3><div>Retrospective cross-sectional study that examined the reproductive outcomes of female patients exposed to systemic ICI therapy.</div></div><div><h3>Subjects</h3><div>Cis-female patients, aged 18–40 years, with advanced-stage melanoma and no prior sterilization procedures or exposure to other systemic antineoplastic therapies who underwent treatment with systemic ICI therapy.</div></div><div><h3>Exposure</h3><div>Systemic ICI treatment as first-line, only-line therapy for advanced-stage melanoma.</div></div><div><h3>Main Outcome Measures</h3><div>Menstrual cycle data, contraceptive use, antimüllerian hormone and follicle-stimulating hormone values, and reproductive outcomes (occurrence of pregnancy) during and after ICI exposure.</div></div><div><h3>Results</h3><div>There were 1,755 female patients with melanoma, aged 18–40 years, evaluated at MD Anderson Cancer Center between the years of 2015 and 2022. We identified 49 cis-females who met inclusion criteria. The most common treatment regimen was nivolumab (44.9%). Among 24 patients employing nonhormonal contraception, 79.2% reported regular menstrual cycle length throughout ICI therapy, with amenorrhea attributed to pregnancy or hypophysitis observed in the minority. Eight patients had a total of nine spontaneous conceptions, with two occurring during ICI therapy and seven after therapy. Limited availability of antimüllerian hormone and follicle-stimulating hormone values precluded conclusive analysis of laboratory markers.</div></div><div><h3>Conclusion</h3><div>Study findings suggest minimal short-term reproductive effects of ICI therapy, with most patients maintaining regular menstrual cycles and no occurrences of primary ovarian insufficiency observed. This study contributes reassuring insights into the short-term reproductive effects of ICI therapy, highlighting the preservation of ovarian function and menstrual regularity.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 420-427"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-10-08DOI: 10.1016/j.xfre.2025.09.009
Sarah C. Cromack M.D. , Kara N. Goldman M.D.
{"title":"Immunotherapy and ovarian function: bridging reproductive health in oncology clinical trials","authors":"Sarah C. Cromack M.D. , Kara N. Goldman M.D.","doi":"10.1016/j.xfre.2025.09.009","DOIUrl":"10.1016/j.xfre.2025.09.009","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 411-412"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-11-05DOI: 10.1016/j.xfre.2025.10.006
Aileen Portugal M.D., Dan I. Lebovic M.D.
{"title":"Should we go with the flow? Rethinking sperm selection through microfluidics","authors":"Aileen Portugal M.D., Dan I. Lebovic M.D.","doi":"10.1016/j.xfre.2025.10.006","DOIUrl":"10.1016/j.xfre.2025.10.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 415-416"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-11-05DOI: 10.1016/j.xfre.2025.10.007
Elizabeth L. Wolfe M.D. , LaTasha B. Craig M.D.
{"title":"Reviewing the 36-hour trigger rule through a global lens","authors":"Elizabeth L. Wolfe M.D. , LaTasha B. Craig M.D.","doi":"10.1016/j.xfre.2025.10.007","DOIUrl":"10.1016/j.xfre.2025.10.007","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Page 417"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-11-05DOI: 10.1016/j.xfre.2025.11.002
Adriana J. Wong M.D., M.P.H., Richard J. Paulson M.D., M.S.
{"title":"RhD immune globulin administration after early pregnancy loss following fertility treatment: time for national guidelines","authors":"Adriana J. Wong M.D., M.P.H., Richard J. Paulson M.D., M.S.","doi":"10.1016/j.xfre.2025.11.002","DOIUrl":"10.1016/j.xfre.2025.11.002","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 409-410"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-12-11DOI: 10.1016/j.xfre.2025.08.002
Diederik L. Smit M.D., Ph.D. , Tijs Verdegaal M.D. , Peter Bond M.Sc.
{"title":"Reply of the authors: Positioning human chorionic gonadotropin therapy for androgen users within a harm reduction framework","authors":"Diederik L. Smit M.D., Ph.D. , Tijs Verdegaal M.D. , Peter Bond M.Sc.","doi":"10.1016/j.xfre.2025.08.002","DOIUrl":"10.1016/j.xfre.2025.08.002","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Page 516"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-09-15DOI: 10.1016/j.xfre.2025.09.004
Thomas T.F. Huang Ph.D. , Sheela Ali Ph.D. , Kyle M. Ishikawa Ph.D. , Hyeong Jun Ahn Ph.D. , Ammon H. Bayles Ph.D. , Shawn E. Gurtcheff M.D. , Nabil Arrach Ph.D. , Santiago Munne Ph.D.
{"title":"Euploidy rates within blastocysts obtained from differently sized cohorts and age groups approximate a binomial distribution","authors":"Thomas T.F. Huang Ph.D. , Sheela Ali Ph.D. , Kyle M. Ishikawa Ph.D. , Hyeong Jun Ahn Ph.D. , Ammon H. Bayles Ph.D. , Shawn E. Gurtcheff M.D. , Nabil Arrach Ph.D. , Santiago Munne Ph.D.","doi":"10.1016/j.xfre.2025.09.004","DOIUrl":"10.1016/j.xfre.2025.09.004","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate whether the distribution of euploid blastocysts within cohorts can be predicted.</div></div><div><h3>Design</h3><div>Retrospective observational study.</div></div><div><h3>Subjects</h3><div>A total of 1,719 autologous egg retrieval cycles for in vitro fertilization from a single center that resulted in blastocysts biopsied for preimplantation genetic testing for aneuploidy.</div></div><div><h3>Exposure</h3><div>Trophectoderm biopsy.</div></div><div><h3>Main Outcome Measures</h3><div>Analysis of the statistical distribution structure of blastocyst euploidy within cohorts as functions of patient age and discrete cohort size.</div></div><div><h3>Results</h3><div>A total of 9,385 blastocyst biopsy results were analyzed. Results were first categorized into the following genotype categories: euploid (61.1%); uniform whole chromosome aneuploid (32.9%); mosaic and/or segmental (3.3%); and inconclusive results (2.7%). Cohorts were then stratified by both age group (<30, 30–34, 35–37, 38–40, 41–42, and ≥43 years) and by cohort size from 1 to 10 blastocysts. Within age groups, the probability that a blastocyst was euploid progressively decreased with increasing age from 74.5% (<30 years) to 19.2% (≥43 years). Within each of the age groups, the probability for euploidy increased as the biopsied cohort size increased from 1 to 10 (odds ratio, 1.03 for each unit increase). Biopsies from younger age groups of <40 years showed predictably smooth increases in the number of e+/cohort as cohort size increased. Notably, the observed distribution of euploids/cohort showed no statistical differences from those expected from theoretical binomial calculations in 52 (91.2%) of 57 discrete subgroups identified by age and biopsied cohort size.</div></div><div><h3>Conclusion</h3><div>The probability distribution structure of euploids within discrete cohort sizes is binomial within all age groups and nearly all cohort sizes. The probability distribution ranges identified represent a more accurate frame of reference that describes and predicts the number of euploid blastocysts most likely to be present within an individual cohort before biopsy compared with estimates from simple age group averages. These results offer new approaches for counseling and clinical decision-making.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 478-486"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum human chorionic gonadotropin can predict live birth 7 days after frozen-thawed blastocyst transfer","authors":"Nobuyuki Kidera Ph.D. , Tomonori Ishikawa Ph.D. , Toshihiro Kawamura M.D. , Naoyuki Miyasaka Ph.D.","doi":"10.1016/j.xfre.2025.10.002","DOIUrl":"10.1016/j.xfre.2025.10.002","url":null,"abstract":"<div><h3>Objective</h3><div>To study the earliest timepoint at which serum human chorionic gonadotropin (hCG) can predict live birth after blastocyst frozen embryo transfer, and to determine the cutoff values for hCG levels on days 7–11 after frozen-thawed embryo transfer with blastocysts.</div></div><div><h3>Design</h3><div>Single-center retrospective cohort study.</div></div><div><h3>Subjects</h3><div>We investigated 18,491 cycles of frozen-thawed blastocyst transfers at our hospital between January 2016 and December 2022.</div></div><div><h3>Exposure</h3><div>Not applicable.</div></div><div><h3>Main Outcome Measures</h3><div>The hCG cutoff values for live birth on days 7–11 after frozen-thawed blastocyst transfer.</div></div><div><h3>Results</h3><div>Receiver operating characteristic analysis between serum hCG levels and live birth after frozen-thawed blastocyst transfer showed area under the curve values of 0.962, 0.958, 0.954, 0.957, and 0.954, for days 7, 8, 9, 10, and 11, respectively. Serum hCG cutoff values from the 7th to 11th days after frozen-thawed blastocyst embryo transfer were 31.05 mIU/mL, 46.6 mIU/mL, 72.05 mIU/mL, 95.4 mIU/mL, and 159.9 mIU/mL, respectively.</div></div><div><h3>Conclusion</h3><div>We determined the hCG cutoff values for live births after frozen-thawed blastocyst transfer. We suggest that it is possible to predict pregnancy outcomes as early as the 7th or 8th day after frozen-thawed blastocyst transfer.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 455-461"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FS ReportsPub Date : 2025-12-01Epub Date: 2025-11-05DOI: 10.1016/j.xfre.2025.10.005
Nicholas A. Deebel M.D. , Joshua A. Halpern M.D., M.S.
{"title":"The utility of high-frequency ultrasound for identification of spermatogenesis","authors":"Nicholas A. Deebel M.D. , Joshua A. Halpern M.D., M.S.","doi":"10.1016/j.xfre.2025.10.005","DOIUrl":"10.1016/j.xfre.2025.10.005","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 413-414"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}